Hyperpolarized 13C MRI of renal mitochondrial dysfunction
肾线粒体功能障碍的超极化 13C MRI
基本信息
- 批准号:10593424
- 负责人:
- 金额:$ 19.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-21 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:AcetoacetatesAddressAffectAnionsBolus InfusionCardiovascular systemCell physiologyChronic DiseaseChronic Kidney FailureClinicalClinical ManagementClinical MarkersContrast MediaCryopreservationCustomDataDetectionDevelopmentDiabetes MellitusDiabetic NephropathyDisease ProgressionEquipmentEstersFormulationFreezingFunctional disorderGenetic ModelsGoalsHeadHealthHematological DiseaseHumanHydrolysisImageImaging TechniquesIsotope LabelingKetone BodiesKidneyKidney DiseasesLaboratoriesLiquid substanceMagnetic Resonance ImagingMeasuresMedical ImagingMetabolicMitochondriaMorbidity - disease rateNon-Insulin-Dependent Diabetes MellitusNuclearObesityOutcomePatientsPerformancePhysiologic pulsePhysiologicalPositron-Emission TomographyProcessProductionProtocols documentationPyruvateRattusReactionResearchRodent ModelRoleSamplingScanningSeriesSignal TransductionSourceSource CodeTechnologyTestingTimeTissuesToxic effectUrologic DiseasesWorkbasebeta-Hydroxybutyratechemical stabilitychemical synthesisclinical translationdata acquisitiondensitydesigndiabetes managementdiabeticexperimental studyimaging biomarkerimaging platformimaging probeimprovedin vivoinnovationinstrumentmitochondrial dysfunctionmitochondrial metabolismmolecular imagingmortalitynovelpreclinical imagingpublic health relevanceradio frequencysimulationsolutespectroscopic imagingtechnology developmenttooltool developmentuptake
项目摘要
PROJECT SUMMARY
Mitochondrial dysfunction is recognized as a key early driver for disease progression in diabetic nephropathy
(DN), among other chronic diseases, yet there exist very few tools for non-invasive assessment of mitochondrial
status. Given that DN is an important source of diabetes-related morbidity and mortality (through its impact on
cardiovascular outcomes), the ability to better understand and potentially even predict the progression of patients
with diabetes to DN could have a large impact on clinical management of diabetes. The purpose of this R21
proposal (“Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases”) is to
develop a new imaging probe with mitochondria-specific reactivity for hyperpolarized (HP) 13C MRI, [1,3-
13C2]acetoacetate (AcAc), providing non-invasive readout of mitochondrial metabolic status. This mitochondria-
targeted ketone body probe has several favorable features with respect to HP 13C technology including long T1
signal lifetime, low toxicity, and rapid cellular uptake, but also has major associated challenges which have
hampered development. To address these, we propose several technical innovations including: 1) improved
chemical synthesis with increased purity and stability, 2) first-ever hyperpolarization on the state-of-the-art
human-scale GE SPINlab 5T instrument, 3) improved formulation for dynamic nuclear polarization (DNP) with
potentially higher polarization levels and shorter buildup times, and 4) highly efficient data acquisition with a
novel pulse sequence employing multi-band spectral-spatial radiofrequency (SSRF) pulse excitation on a new
MR/PET preclinical imaging platform (MR Solutions). The cumulative impact of these innovations is expected to
provide a sensitivity gain of more than an order of magnitude over recent limited “proof of concept” work,
propelling HP [1,3-13C2]AcAc into a powerful new imaging-based tool for assessing mitochondrial health.
The tool will be evaluated in a well-characterized rodent model of DN, to directly test the hypothesis that HP [1-
13C]AcAc can detect early DN prior to clinically detectable manifestations. Lastly, consistent with the FOA, we
are committed to a clear plan for sharing the newly developed “Catalytic Tool” with potential users (>30 labs with
the necessary equipment for HP 13C MRI), including sharing all protocols for chemical synthesis and formulation,
as well as sharing all pulse sequence source code, novel SSRF pulse waveforms, and data from the study online.
项目摘要
线粒体功能障碍被认为是糖尿病肾病疾病进展的关键早期驱动因素
(DN),在其他慢性疾病中,但用于线粒体非侵入性评估的工具很少。
status.鉴于DN是糖尿病相关发病率和死亡率的重要来源(通过其对糖尿病的影响),
心血管结局),更好地理解甚至潜在地预测患者进展的能力
糖尿病合并DN可能对糖尿病的临床管理产生很大影响。R21的目的
提案(“肾脏、泌尿系统和血液系统疾病的催化工具和技术开发”)的目的是
开发具有超极化(HP)13 C MRI的ESTA特异性反应性的新成像探针,[1,3-
13 C2]乙酰乙酸(AcAc),提供线粒体代谢状态的非侵入性读出。线粒体-
相对于HP 13 C技术,靶向酮体探针具有几个有利的特征,包括长T1
信号寿命、低毒性和快速细胞摄取,但也具有主要的相关挑战,
阻碍了发展。为了解决这些问题,我们提出了几项技术创新,包括:1)改进
化学合成,纯度和稳定性提高,2)最先进的首次超极化
人规模GE SPINlab 5 T仪器,3)动态核极化(DNP)的改进制剂,
潜在的更高的极化水平和更短的建立时间,以及4)使用
一种新的脉冲序列,采用多波段频谱空间射频(SSRF)脉冲激励的新的
MR/PET临床前成像平台(MR Solutions)。预计这些创新的累积影响将
提供了比最近有限的“概念证明”工作多一个数量级的灵敏度增益,
推动HP [1,3 - 13 C2]AcAc成为评估线粒体健康的强大的新成像工具。
该工具将在良好表征的DN啮齿动物模型中进行评价,以直接检验HP [1- 10]
13 C]AcAc可在临床可检测的表现之前检测早期DN。最后,与FOA一致,我们
致力于制定明确的计划,与潜在用户共享新开发的“催化工具”(超过30个实验室,
HP 13 C MRI的必要设备),包括共享化学合成和配制的所有方案,
以及分享所有的脉冲序列源代码,新的SSRF脉冲波形,以及在线研究的数据。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Cornelius von Morze其他文献
Cornelius von Morze的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Cornelius von Morze', 18)}}的其他基金
Hyperpolarized 13C MRI of renal mitochondrial dysfunction
肾线粒体功能障碍的超极化 13C MRI
- 批准号:
10707325 - 财政年份:2022
- 资助金额:
$ 19.69万 - 项目类别:
Molecular Imaging of Renal Transport and Metabolism using Hyperpolarized C-13 MRI
使用超极化 C-13 MRI 进行肾脏运输和代谢的分子成像
- 批准号:
8820261 - 财政年份:2014
- 资助金额:
$ 19.69万 - 项目类别:
Molecular Imaging of Renal Transport and Metabolism using Hyperpolarized C-13 MRI
使用超极化 C-13 MRI 进行肾脏运输和代谢的分子成像
- 批准号:
8701110 - 财政年份:2014
- 资助金额:
$ 19.69万 - 项目类别:
Molecular Imaging of Renal Transport and Metabolism using Hyperpolarized C-13 MRI
使用超极化 C-13 MRI 进行肾脏运输和代谢的分子成像
- 批准号:
9249529 - 财政年份:2014
- 资助金额:
$ 19.69万 - 项目类别:
Molecular Imaging of Renal Transport and Metabolism using Hyperpolarized C-13 MRI
使用超极化 C-13 MRI 进行肾脏运输和代谢的分子成像
- 批准号:
9040160 - 财政年份:2014
- 资助金额:
$ 19.69万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 19.69万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 19.69万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 19.69万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 19.69万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 19.69万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 19.69万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 19.69万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 19.69万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 19.69万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 19.69万 - 项目类别:
Research Grant